Back to Search
Start Over
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
- Source :
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 62, iss 12, Journal of Nuclear Medicine, 62(12), 1712-1718. Society of Nuclear Medicine and Molecular Imaging
- Publication Year :
- 2021
- Publisher :
- Society of Nuclear Medicine, 2021.
-
Abstract
- We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 d per 4 wk, respectively, compared with 0.99, 1.44, and 2.54 d for high-dose octreotide LAR. The mean differences were 3.11 d (95% CI, 1.35–4.88; P = 0.0007) for abdominal pain, 3.11 d (1.18–5.04; P = 0.0017) for diarrhea, and 1.98 d (0.08–3.88; P = 0.0413) for flushing, favoring 177Lu-DOTATATE. A positive repeated-measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing. Conclusion: In addition to efficacy and quality-of-life benefits, symptom diaries from NETTER-1 demonstrated that treatment with 177Lu-DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut neuroendocrine tumors, compared with high-dose octreotide LAR, supporting a beneficial effect of 177Lu-DOTATATE on health-related quality of life. Title in Web of Science: Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with Lu-177-DOTATATE
- Subjects :
- medicine.medical_specialty
Abdominal pain
Clinical Trials and Supportive Activities
Clinical Sciences
Octreotide
030204 cardiovascular system & hematology
Neuroendocrine tumors
Gastroenterology
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Quality of life
Clinical Research
Internal medicine
lutetium-177
medicine
Radiology, Nuclear Medicine and imaging
Cancer och onkologi
NETTER-1
business.industry
Pain Research
Radionuclide Therapy
Repeated measures design
177Lu
medicine.disease
Confidence interval
symptom diary
Nuclear Medicine & Medical Imaging
Diarrhea
Neuroendocrine
Cancer and Oncology
030220 oncology & carcinogenesis
Radionuclide therapy
Endocrine [Oncology]
Radiologi och bildbehandling
Chronic Pain
medicine.symptom
Digestive Diseases
business
Radiology, Nuclear Medicine and Medical Imaging
medicine.drug
Subjects
Details
- ISSN :
- 2159662X and 01615505
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Journal of Nuclear Medicine
- Accession number :
- edsair.doi.dedup.....9e3c2d6cd0409f21dbd06f05d21eaff1